Literature DB >> 35449799

Cardiac Complications of Myeloproliferative Disorders.

Muhammad Wasif Saif1, Umer Khan2, Bernard R Greenberg3.   

Abstract

Thrombosis occurs in about one-third of cases of myeloproliferative disorders, contributing to a mortality rate of 15% to 40%. It may involve the arteries and veins, including hepatic, mesenteric, and portal, and even the cardiac circulation. Cardiovascular involvement varies from 4% to 21%. Acute ischemic coronary artery disease may be at the root of presenting symptoms of such disorders, particularly in younger patients. The authors review the literature linking cardiac diseases with myeloproliferative disorders and advise a high degree of suspicion for an underlying myeloproliferative disorder in a young patient presenting with cardiac disease with no known risk factors.

Entities:  

Year:  2001        PMID: 35449799      PMCID: PMC9020383     

Source DB:  PubMed          Journal:  Resid Staff Physician        ISSN: 0034-5555


  35 in total

1.  Pulmonary hypertension associated with long-standing thrombocytosis.

Authors:  C Rostagno; D Prisco; R Abbate; L Poggesi
Journal:  Chest       Date:  1991-05       Impact factor: 9.410

Review 2.  Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase.

Authors:  F Guilhot; L Lacotte-Thierry
Journal:  Hematol Cell Ther       Date:  1998-10

Review 3.  Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.

Authors:  A Tefferi; M N Silverstein; R M Petitt; R A Mesa; L A Solberg
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

Review 4.  Bleeding and thrombosis in the myeloproliferative disorders.

Authors:  A I Schafer
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

5.  Uncontrolled thrombocytosis in chronic myeloproliferative disorders.

Authors:  C M Kessler; H G Klein; R J Havlik
Journal:  Br J Haematol       Date:  1982-01       Impact factor: 6.998

6.  Pulmonary hypertension in polycythemia vera.

Authors:  S Nand; E Orfei
Journal:  Am J Hematol       Date:  1994-11       Impact factor: 10.047

7.  Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases.

Authors:  G García-Manero; S J Schuster; H Patrick; J Martinez
Journal:  Am J Hematol       Date:  1999-02       Impact factor: 10.047

8.  Pulmonary arteritis with pulmonary arterial thrombosis and recurrent endopulmonary embolization.

Authors:  U Wagner; A Bittinger; P von Wichert; P J Barth
Journal:  Clin Investig       Date:  1993-07

9.  Platelet von Willebrand factor abnormalities in myeloproliferative syndromes.

Authors:  G Castaman; A Lattuada; M Ruggeri; A Tosetto; P M Mannucci; F Rodeghiero
Journal:  Am J Hematol       Date:  1995-08       Impact factor: 10.047

10.  Essential thrombocythemia in young adults.

Authors:  K J McIntyre; H C Hoagland; M N Silverstein; R M Petitt
Journal:  Mayo Clin Proc       Date:  1991-02       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.